PTIEのニュース
Pain Therapeutics Announces Name Change to Cassava Sciences, Inc. 2019/03/27 12:30:00 Benzinga
AUSTIN, Texas, March 27, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (NASDAQ: PTIE ), a drug development company, announced a company name change to Cassava Sciences, Inc., effective immediately. The new name was chosen to better reflect the Company's strategic focus on drug development for neurodegenerative diseases, such as Alzheimer's disease. Beginning March 28, 2019, Cassava Sciences will trade on NASDAQ under the new ticker symbol: SAVA. "A new Company name is part of a larger rebranding effort around neurodegenerative diseases, such as Alzheimer's disease," said Remi Barbier, Chairman, President & CEO of Cassava Sciences. "One thing that won't change is our focus on developing potential breakthrough innovations and an unwavering dedication to improve people's lives. This emphasis has characterized our history and remains core to our strategy today." Cassava Sciences is in Phase II clinical testing with a new drug candidate to treat patients with Alzheimer's disease. The Company's Phase II study is being conducted with scientific and financial support from the National Institutes of Health (NIH).
Pain Therapeutics Announces Name Change to Cassava Sciences, Inc. 2019/03/27 12:30:00 Benzinga
AUSTIN, Texas, March 27, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (NASDAQ: PTIE ), a drug development company, announced a company name change to Cassava Sciences, Inc., effective immediately. The new name was chosen to better reflect the Company's strategic focus on drug development for neurodegenerative diseases, such as Alzheimer's disease. Beginning March 28, 2019, Cassava Sciences will trade on NASDAQ under the new ticker symbol: SAVA. "A new Company name is part of a larger rebranding effort around neurodegenerative diseases, such as Alzheimer's disease," said Remi Barbier, Chairman, President & CEO of Cassava Sciences. "One thing that won't change is our focus on developing potential breakthrough innovations and an unwavering dedication to improve people's lives. This emphasis has characterized our history and remains core to our strategy today." Cassava Sciences is in Phase II clinical testing with a new drug candidate to treat patients with Alzheimer's disease. The Company's Phase II study is being conducted with scientific and financial support from the National Institutes of Health (NIH).